Clinical News
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in β-Thalassaemia
3 giorni ago
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in β-Thalassaemia
Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin, announced dosing of the first patient…
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
1 settimana ago
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
2 settimane ago
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Fulcrum Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…
Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU
3 settimane ago
Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU
Bluebird Bio’s investigational gene therapy LentiGlobin has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of sickle cell disease (SCD). Given to candidate therapies with promising clinical data for diseases of high…
Health Canada Approves REBLOZYL® For Adult Patients with β-Thalassaemia
3 settimane ago
Health Canada Approves REBLOZYL® For Adult Patients with β-Thalassaemia
Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia…
COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine
4 settimane ago
COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine
As large parts of the world prepare for a second wave of coronavirus cases governments have pinned their hopes on the rapid development of a vaccine to provide a route…
AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt
Settembre 14, 2020
AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt
AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…
AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold
Settembre 9, 2020
AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold
The pharmaceutical company AstraZeneca halted large, late-stage global trials of its coronavirus vaccine on Tuesday, because of a serious suspected adverse reaction in a participant. It is not yet known…
AstraZeneca Starts U.S. Final-Stage Trial of Covid-19 Vaccine
Settembre 2, 2020
AstraZeneca Starts U.S. Final-Stage Trial of Covid-19 Vaccine
AstraZeneca Plc has begun final-stage, Phase III trial of its coronavirus vaccine AZD1222 in the U.S., according to the company´s latest statement. Trial centers across the US are recruiting up to 30,000 adults aged 18 years…
Pfizer Has Reached Over 50% Enrollment for Coronavirus Vaccine Candidate Phase 3 Trial
Agosto 27, 2020
Pfizer Has Reached Over 50% Enrollment for Coronavirus Vaccine Candidate Phase 3 Trial
One of the leading COVID-19 vaccine candidates currently in development is getting closer to a potential finish line. Pfizer said on Wednesday that the recruitment for the crucial U.S. phase 3 clinical…